Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Pembrolizumab (MK-3475) in Hepatitis C Virus Positive and Negative Subjects With Advanced Hepatocellular Carcinoma Who Progressed on or Were Intolerant to First-Line Systemic Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02940496
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:35.595897+00:00
Published At
2025-07-15T00:00:00+00:00
Record Updated At
2025-07-15
Results Posted At
2025-07-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["BCLC Stage B Hepatocellular Carcinoma", "BCLC Stage C Hepatocellular Carcinoma", "Hepatitis C Infection", "Refractory Liver Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v7", "Stage IIIA Hepatocellular Carcinoma AJCC v7", "Stage IIIB Hepatocellular Carcinoma AJCC v7", "Stage IIIC Hepatocellular Carcinoma AJCC v7", "Stage IV Hepatocellular Carcinoma AJCC v7", "Stage IVA Hepatocellular Carcinoma AJCC v7", "Stage IVB Hepatocellular Carcinoma AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-07-15"
protocolSection.identificationModule.nctId
"NCT02940496"
protocolSection.identificationModule.officialTitle
"A Phase II Study of Pembrolizumab (MK-3475) in Hepatitis C Virus Positive and Negative Subjects With Advanced Hepatocellular Carcinoma Who Progressed on or Were Intolerant to First-Line Systemic Therapy"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-07-15"

Study condition terms

  • BCLC Stage B Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • BCLC Stage C Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Hepatitis C Infection (protocolSection.conditionsModule.conditions)
  • Refractory Liver Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Hepatocellular Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Hepatocellular Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Hepatocellular Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Hepatocellular Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Hepatocellular Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVA Hepatocellular Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVB Hepatocellular Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.